使用新型即用型可注射硅酸钙基封闭剂进行根管治疗的2年临床疗效:一项多中心随机对照试验
这项多中心、前瞻性、随机、评估者盲法、对照、非劣效性试验纳入160例需行根管治疗的患者,比较可注射硅酸钙基封闭剂BioRoot Flow与手混型BioRoot RCS的24个月疗效与安全性。结果显示两组24个月成功率分别为86.6%和87.7%(p=.0195),无显著差异,未报告不良事件,支持新材料的非劣效性。
要点
- BioRoot Flow组24个月成功率为86.6%,BioRoot RCS组为87.7%(p=.0195)。
- 两组在各项次要结局上均未观察到显著差异,未报告不良事件。
- 研究支持新型可注射硅酸钙基封闭剂在临床实践中的应用。
核心结论
- 研究证明新型可注射硅酸钙基封闭剂BioRoot Flow在疗效和安全性方面不劣于手混型BioRoot RCS,支持新材料在临床实践中的应用。
研究设计与样本
- 多中心、前瞻性、随机、评估者盲法、对照、非劣效性试验(ClinicalTrials.gov: NCT04757753)。
- 共纳入160例需行单根或多根牙原发性或继发性根管治疗的患者,平均年龄48岁,BioRoot Flow组77例,BioRoot RCS组83例。
- 采用区组随机分配,主要结局为基于临床和影像学标准的24个月成功率;非劣效性界值设为13%,把握度80%,单侧α风险5%。
- 研究者和患者对分配的医疗器械未设盲,由两名合格评估者对根尖周X线片进行盲法独立中心评估。
主要发现
- 24个月随访率为85.6%。
- BioRoot Flow组24个月成功率为86.6%,BioRoot RCS组为87.7%(p=.0195)。
- 两组在6个月和12个月成功率、充填质量、超填材料吸收、术后疼痛及不良事件等次要结局方面均未观察到显著差异。
- 未报告不良事件。
关键数值与推荐
- 非劣效性界值为13%,把握度80%,单侧α风险5%。
- 24个月总体成功率BioRoot Flow组86.6% vs BioRoot RCS组87.7%(p=.0195)。
临床怎么用
- 研究结论支持将新型可注射硅酸钙基封闭剂BioRoot Flow应用于临床实践。
局限性
- 研究者和患者对分配的医疗器械未设盲。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Calcium silicate-based sealers (CSSs) have gained popularity in endodontic applications primarily due to their biological properties and ease of use. This study aimed to assess the 24-month efficacy and safety of root canal treatment using a new injectable CSS, BioRoot™ Flow, and to demonstrate the non-inferiority compared to the established hand-mixed BioRoot™ RCS. METHODOLOGY: This was a multicentric, prospective, randomised, assessor-blinded, controlled, non-inferiority trial (ClinicalTrials.gov: NCT04757753). Patients requiring a primary or a secondary root canal treatment on a single or multi-rooted tooth were block randomly assigned to BioRoot Flow or BioRoot RCS groups. The primary outcome was the 24-month success rate based on clinical and radiological criteria. Secondary outcomes included the 6- and 12-month success rates based on similar radiological and clinical criteria, quality of obturation, resorption of extruded material in case of overfilling assessed at 6, 12 and 24 months, post-operative pain measured using the Visual Analog Scale (VAS) at baseline, 12 h, 24 h, 48 h, 72 h and 7 days, and occurrence of adverse events. A subgroup analysis was also performed based on the type of treatment and on the presence or absence of apical periodontitis (AP) at baseline. Non-inferiority between materials was assessed using Dunnett and Gent's Chi-squared (χ2) test, based on an initial hypothesis with a non-inferiority margin set at 13%, an 80% power and a 5% one-sided alpha risk. Investigators and patients were not blinded to the assigned medical device. Two qualified evaluators performed a blinded independent central review of the retro-alveolar radiographs. RESULTS: A total of 160 patients with a mean age of 48 years were treated (77 in BioRoot Flow and 83 in BioRoot RCS). The 24-month follow-up rate was 85.6%. The overall 24-month success rates were 86.6% and 87.7% (p = .0195), respectively. No significant differences were observed between the groups regarding any of the considered secondary outcomes. No adverse events were reported. CONCLUSION: This study demonstrated the non-inferiority of the new injectable CSS (BioRoot Flow) compared to the previous hand-mixed version (BioRoot RCS) in terms of efficacy and safety, supporting the implementation of the new material in clinical practice.
引用
- Simon S, Beauquis J, Colombel H, et al. Clinical efficacy of root canal treatment at 2 years using a new ready-to-use injectable calcium silicate-based sealer: A multicentric randomised controlled trial. Int Endod J. 2025. PMID: 40491343. doi:10.1111/iej.14265
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。